NEWJoin 2M+ software buyers|Get Weekly Insights, Trends & Expert PicksSubscribe free →

Ibex - AI Medical Diagnostic Platforms

Ibex Review: Is It The Right AI Medical Diagnostic Platforms For Your Team?

Best for Mid-market · Enterprise

Add to compare

Ibex offers custom pricing plan

Get Pricing Details

Ibex Medical Analytics supports cancer diagnosis on digitised slides. The Ibex Breast Suite covers breast tissue with HER2, ER, PR and Ki-67 scoring and a separate product for lymph node metastases, alongside Ibex Prostate with Gleason grading and Ibex Gastric, all running on a shared platform with prospective quality control. Buyers are pathology laboratories and pathologists, and the vendor is extending the platform into biopharma research. Its breast page states that the platform includes products that are CE-IVD certified and registered with the MHRA in the UK and with regulators in Australia, Brazil, Israel and Switzerland, that it includes one product that is FDA cleared, and that others are research use only in the United States. The FDA cleared product is not named and no clearance number is given. No price is published.

Pricing

  • Ibex offers custom pricing plan

Best For

Designed for mid-market and enterprise teams

Ibex was reviewed internally using user feedback, in-house testing, and market research to assess its performance, reliability, and user experience. Learn how we review products and our evaluation process.

Who should consider Ibex

Team types
Medium Business, Large Enterprises

Ready to try it?

Get started with Ibex

Connect with the team for a personalised demo.

Get Pricing Details

What is the pricing of Ibex?

Ibex uses custom pricing — plans are tailored to your team size and needs. Contact them for a quote.

Free TrialNot available
PricingIbex offers custom pricing
Pricing Model
Quotation Based

Weighing your options?

Not sure if Ibex fits your budget?

Ibex reviews and ratings

Buyer sentiment

No reviews exist for this product in this catalogue, so no buyer sentiment can be reported.

Be the first to review Ibex

You'll help thousands of buyers make a smarter decision.

Spotsaas advisor
Get a custom demo of Ibex
  • See if Ibex fits your business
  • Real pricing — no sales pressure
  • A demo or quick answers, your call

Step 1 of 4

How big is your team?

We tailor recommendations to companies your size.

Trusted by teams at

What are the features of Ibex?

29%

Feature coverage

4 of 14 tracked features

Biomarker scoring quantifies a stain on a tissue slide, returning a figure for markers such as HER2, PD-L1, ER, PR or Ki-67 instead of a pat…

Lesion detection marks the region of a study where the software believes an abnormality is present, such as a fracture on a plain film, a no…

Quantitative analysis turns an image into numbers: plaque volume, chamber dimensions, breast density, lesion size, perfusion maps or a segme…

Worklist prioritization places the AI result into the reading list the radiologist already works from, moving a flagged study up the queue a…

Help & Contact

Ibex Support Options

Customer ServiceOnline

Frequently Asked Questions About Ibex

Common questions buyers ask before choosing Ibex.

Ibex is a AI Medical Diagnostic Platforms. Ibex offers Lesion Detection, Biomarker Scoring, Quantitative Analysis and many more functionalities.

Ibex offers Quotation Based pricing model

We don't have information regarding integrations of the Ibex as of now.

The starting price is not disclosed by Ibex. You can visit Ibex pricing page to get the latest pricing.

Ready to try it?

Get started with Ibex

Get connected with the team for a personalised demo.

About the reviewer

Rajat Gupta is the founder of Spotsaas, where he has built software research covering 25,000+ products across CRM, HR, AI, and finance. He applies hands-on product research and a background in commerce and the CFA program to evaluate software through a business and ROI lens. His goal: help teams make software decisions they won't regret.

Disclaimer: This research has been collated from a variety of authoritative sources. We welcome your feedback at [email protected].